Mittwoch, 24.06.2026, Calendar Week 26, 175. day of the year, 190 days remaining until EoY.

Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.

Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US05370A1088

Filter zurücksetzen

Do you already know our new terminal view? Click here.

FIGI: BBG00FQ7LXW1

RNAM

Avidity Biosciences, Inc.

GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH

NAME

Avidity Biosciences, Inc.

ISIN

US05370A1088

TICKER

RNAM

MIC

XNAS

REUTERS

RNA.OQ

BLOOMBERG

RNAM US

Di., 23.06.2026 Avidity Biosciences

Newsfeed

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Atrium Therapeutics Reports First Quarter 2026 Financial Results | Avidity Biosciences, Inc.

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | Avidity Biosciences, Inc.

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference | Avidity Biosciences, Inc.

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders | Avidity Biosciences, Inc.

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 | Avidity Biosciences, Inc.

Avidity Biosciences Announces Expected Record Date for Spin-Off | Avidity Biosciences, Inc.

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 | Avidity Biosciences, Inc.

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Avidity Biosciences, Inc.

Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders | Avidity Biosciences, Inc.

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders | Avidity Biosciences, Inc.

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA | Avidity Biosciences, Inc.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA) | Avidity Biosciences, Inc.

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG | Avidity Biosciences, Inc.

Avidity Biosciences to Participate in Upcoming Investor Conference | Avidity Biosciences, Inc.

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | Avidity Biosciences, Inc.

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society | Avidity Biosciences, Inc.

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | Avidity Biosciences, Inc.

Avidity Biosciences Announces Proposed Public Offering of Common Stock | Avidity Biosciences, Inc.

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 | Avidity Biosciences, Inc.

Avidity Biosciences to Participate in Upcoming Investor Conferences | Avidity Biosciences, Inc.

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission | Avidity Biosciences, Inc.

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping | Avidity Biosciences, Inc.

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress | Avidity Biosciences, Inc.

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | Avidity Biosciences, Inc.

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights | Avidity Biosciences, Inc.

Avidity Biosciences to Participate in Upcoming Investor Conference | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 | Avidity Biosciences, Inc.

Avidity Biosciences to Participate in Upcoming Investor Conference | Avidity Biosciences, Inc.

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping i | Avidity Biosciences, Inc.

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference | Avidity Biosciences, Inc.

Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights | Avidity Biosciences, Inc.

Avidity Biosciences to Participate in Upcoming Investor Conferences | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences to Participate in Upcoming Investor Conference | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations | Avidity Biosciences, Inc.

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Avidity Biosciences, Inc.

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 | Avidity Biosciences, Inc.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Avidity Biosciences, Inc.